Formula: | C20H14ClN3O |
Molecular Weight: | 347.80 |
Rotatable Bond Donors: | 3 |
clogP: | 5.16 |
Topological Polar Surface Area: | 61.80 |
Lipinski's RO5: | MW: 347.80 HBA: 4 HBD: 2 RB: 3 LogP: 5.16 |
Rule of Three: | MW: 347.80 HBA: 4 HBD: 2 RB: 3 LogP: 5.16 |
|
DB |
---|
ZINC ID | Similarity | Structure | SDF |
---|
ZINC ID | Similarity | Structure | SDF | |
---|---|---|---|---|
ZINC28563889 | 0.84 | ZINC28563889 RDKit 3D 25 28 0 0 0 0 0 0 0 0999 V2000 -3.8785 -2.8977 -1.6790 O 0 0 0 0 0 0 0 0 0 0 0 0 -3.4529 -1.9408 -0.8058 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.1109 -1.5760 -0.8376 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.6340 -0.5907 0.0294 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.2259 -0.2586 0.0183 C 0 0 0 0 0 0 0 0 0 0 0 0 0.7302 -1.2306 -0.1901 N 0 0 0 0 0 0 0 0 0 0 0 0 1.8990 -0.6273 -0.0950 C 0 0 0 0 0 0 0 0 0 0 0 0 3.2120 -1.2406 -0.2318 C 0 0 0 0 0 0 0 0 0 0 0 0 3.3180 -2.6089 -0.4928 C 0 0 0 0 0 0 0 0 0 0 0 0 4.5669 -3.2122 -0.6268 C 0 0 0 0 0 0 0 0 0 0 0 0 5.7240 -2.4492 -0.5005 C 0 0 0 0 0 0 0 0 0 0 0 0 5.6319 -1.0851 -0.2405 C 0 0 0 0 0 0 0 0 0 0 0 0 4.3810 -0.4856 -0.1072 C 0 0 0 0 0 0 0 0 0 0 0 0 1.7063 0.7040 0.1605 N 0 0 0 0 0 0 0 0 0 0 0 0 0.3618 0.9848 0.2120 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.1346 2.3451 0.3890 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.3326 2.7533 -0.1934 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.7435 4.0645 -0.0137 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.0483 4.9830 0.6893 N 0 0 0 0 0 0 0 0 0 0 0 0 0.1127 4.5665 1.2355 C 0 0 0 0 0 0 0 0 0 0 0 0 0.6088 3.2783 1.1117 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.5114 -0.0035 0.9435 C 0 0 0 0 0 0 0 0 0 0 0 0 -3.8559 -0.3705 0.9714 C 0 0 0 0 0 0 0 0 0 0 0 0 -4.3286 -1.3416 0.0934 C 0 0 0 0 0 0 0 0 0 0 0 0 -5.9955 -1.7606 0.1602 Cl 0 0 0 0 0 0 0 0 0 0 0 0 1 2 1 0 2 3 2 0 3 4 1 0 4 5 1 0 5 6 1 0 6 7 2 0 7 8 1 0 8 9 2 0 9 10 1 0 10 11 2 0 11 12 1 0 12 13 2 0 7 14 1 0 14 15 1 0 15 16 1 0 16 17 2 0 17 18 1 0 18 19 2 0 19 20 1 0 20 21 2 0 4 22 2 0 22 23 1 0 23 24 2 0 24 25 1 0 24 2 1 0 15 5 2 0 21 16 1 0 13 8 1 0 M END $$$$ |
Name | Assay stage | Target | Activity |
---|---|---|---|
Single dose inhibition of SARS-CoV-2 cytopathic effect in VeroE6 | primary assay | Organism Severe acute respiratory syndrome-related coronavirus | inactive |
Single dose inhibition of SARS-CoV-2 3CL-Pro | primary assay | Replicase polyprotein 1ab | inactive |